Published: 2022 June 06
Soft Tissue Sarcoma Market Size, Competitive Landscape and Market Forecast - 2030
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Soft Tissue Sarcoma Market is segmented by Disease Type (Local sarcoma, Regional sarcoma, Metastatic sarcoma), by Treatment (Radiation Therapy, Chemotherapy, Targeted therapy, Anti-angiogenesis drugs, and Other Treatments), By End-User (Hospitals, Oncology Centers and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030


Market Overview

The Global Soft Tissue Sarcoma Market is expected to grow at a CAGR 8.8% during the forecasting period (2022-2029).

Soft Tissue Sarcoma Market Scope



Market CAGR


Segments Covered

 By Disease Type, By Treatment, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America


To Get a Free Sample Click here


  • Increasing prevalence of soft tissue sarcoma, rising Research and Development activities on drugs and other therapies, are some of the growth factors boosting the growth of the market. Soft tissue sarcoma is a type of cancer that grows from tissues such as nerves, muscles, fats, blood vessels, and thick skin tissues.
  • There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, Kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others. There are several drugs used for the treatment of soft tissue sarcomas such as sunitinib (Sutent), trabectedin (yondelis), sirolimus (Rapamune), bevacizumab (Avastin), doxorubicin (adriamycin), and others.

Soft Tissue Sarcoma Market Analysis

  • In Oct 2016, U.S. Food and Drug Administration approved Eli Lilly and Company¬ís drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types of soft tissue carcinoma.Clinical Trial Analysis:Total Soft Tissue Sarcoma Studies: 1567
  • By Disease Type, the market is segmented into Local sarcoma, Regional sarcoma, and Metastatic sarcoma. By treatment type, the soft tissue sarcoma market is segmented into radiation therapy, targeted therapy, chemotherapy, anti-angiogenesis drugs, and Others.
  • Chemotherapy has the largest market share in the soft tissue sarcoma market. Further, by End-user, the market has been segmented into hospitals, oncology centers, and Others. Hospitals are dominating the global soft tissue sarcoma market during the forecast period due to increasing number of patients getting treatment at hospitals for soft tissue sarcoma and other relevant cancers.

Soft Tissue Sarcoma Geography Shares

  • Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW. North America is leading the global soft tissue sarcoma market due to the high prevalence of cancer and soft tissue sarcoma. According to the American Cancer Society, there were more than 11,500 new cases of soft tissue sarcoma were diagnosed in the U.S. in 2014. Asia-Pacific region is also growing due to rising awareness about increasing advanced treatments for cancer.
  • The major players of global Soft Tissue Sarcoma market include GlaxoSmithKline plc, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Genentech), Johnson & Johnson Services, Teva Pharmaceutical Industries Ltd Celgene Corporation, and others.
  • Some recently approved drugs for the treatment of Soft Tissue Sarcoma are:
  •  In June 2018, Taiwan Liposome Company, (TLC), a clinical-stage specialty pharmaceutical company declared the submission of an Investigational New Drug (IND) application with the U. S. FDA to initiate a Phase I/II, open-label, dose-escalation clinical trial of TLC178, a NanoX liposomal formulation of the anticancer drug vinorelbine, in pediatric rhabdomyosarcoma (a type of soft tissue sarcoma) patients.
  • The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Trending Topics

Ruxolitinib Market

Gynecological Cancers Therapeutics Market

Leukemia Therapeutics Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy